ClinicalTrials.gg
Status unknownNCT03673215Updated Mar 23, 2020

The Tolerability,Safety,PK/PD Study of rhTPO in the Patients With Liver Function Impairment

An Early Phase 1 interventional study of Recombinant human thrombopoietin and Recombinant human thrombopoietin in Liver Cirrhosis, sponsored by Shenyang Sunshine Pharmaceutical Co., LTD.. Status unknown at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-03-23.

Sponsored by Shenyang Sunshine Pharmaceutical Co., LTD. (part of 3SBio Inc.) · Early Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2020), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 214 studies in Liver Cirrhosis with a site in China — 65 open to participants now, 73 under way, 4 of them phase 3. Liver Cirrhosis · China.

Planned enrollment
96th of 127
58 · median 120
Started
2018
with 11 others
Phase 1
11 of 214
2 open now
Registered
80th of 214
by date

Among the 214 studies in Liver Cirrhosis with a site in China, this one is the 96th largest by planned enrollment of the 127 interventional ones that give a count, is one of 12 that started in 2018, is one of 11 in phase 1, and was the 80th registered.

Liver Cirrhosis

1,301 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

65 of the 214 studies in Liver Cirrhosis with a site in China are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 214 studies in Liver Cirrhosis with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the tolerability, safety, pharmacokinetics and pharmacodynamics of recombinant human thrombopoietin in the patients with different degree of liver function impairment according Child- Pugh class.

Read the detailed description

This is a randomized, double-blind, placebo controlled, dose-escalation phase Ia study to evaluate the tolerability, safety, pharmacokinetics and pharmacodynamics of recombinant human thrombopoietin. According Child- Pugh class of liver function impairment and different dose of recombinant human thrombopoietin, nine arms be designed in this study. Each subject in Arm A will be only administered recombinant human thrombopoietin. Each subject in Arm B and C will be randomly assigned to accept either recombinant human thrombopoietin or placebo in 5:1 ratio.

03

Conditions studied

  • Liver Cirrhosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Patients with cirrhosis caused by chronic liver disease who have been diagnosed by /imaging ( class A, B, and C).
    1. ≥3 months.
    1. count≤80×109/ L.
    1. Fertile female subjects with a negative pregnancy test during the screening period and who agree to take effective methods Throughout the study period will be eligible for this study.
    1. Voluntary written .

Exclusion criteria

Exclusion Criteria:

  • 1 Subjects allergic to any component of drug.
  • 2 Subjects with cirrhosis caused by drug-induced liver injury.
  • 3 Subjects with history of splenectomy or liver transplantation.
  • 4 Liver cirrhosis with serious complications, including: hepatic encephalopathy, intractable ascites, upper gastrointestinal bleeding, etc.
  • 5 Subjects with Liver failure.
  • 6 Tthe presence of portal vein thrombosis or tumor thrombus was indicated by doppler ultrasound or CT or MRI and other imaging examinations within 3 months prior to the beginning of screening.
  • 7 Subjects with history of arterial or venous thromboembolism, or with thromboembolic disease, or with high risk factors for thrombosis, or with a hereditary tendency to thrombosis, including Antithrombin III deficiency, etc.
  • 8 Subjects with history of any disease other than chronic liver disease and cirrhosis that may result in decreased count and/or abnormal platelet function, including aplastic anemia, myelodysplastic syndrome (MDS), bone marrow fibrosis, etc.;
  • 9 Subjects with diseases with higher bleeding risk, such as coagulation factor deficiency or Vascular pseudohemophilia factor deficiency.
  • 10 Subjects with severe infections that are not effectively controlled.
  • 11 Past or present history with any serious disease except liver disease, including: angina, severe arrhythmia, myocardial infarction, heart failure, Cerebral hemorrhage, cerebral infarction, intracranial infection, Renal insufficiency( rate ≤50 mL/min ),as well as any other diseases that have been judged by investigator to be unsuitable for this study.
  • 12 Subjects who had undergone trans jugular intrahepatic portal shunt (TIPS);
  • 13 Subjects with Anti- positive antibodies or Anti- TPHA positive antibodies.
  • 14 Subjects who received any therapy with increased platelet count within the 3 weeks or platelet transfusion within 2 weeks before randomization.
  • 15 No more than 30 days or 5 half-lives after investigational drug treatment for other studies (whichever is longer).
  • 16 Subjects with history of primary liver cancer, or an other malignant tumor.
  • 17 patients with WHO≥grade 2 of existing active bleeding, or with history of active bleeding within 2 weeks before randomization.
  • 18 Pregnant or breast-feeding women.
  • 19 Women who have a pregnancy plan within 3 months.
  • 20 Subjects with history of drug abuse and alcoholism within 6 months prior to enrollment.
  • 21 Subjects who do not have the sufficient ability of understanding,communication and cooperation leading to failure to ensure compliance with protocol will be excluded.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
58 participants (estimated)

Study arms

  • Experimental
    A

    Drug: Recombinant human thrombopoietin

  • Experimental
    B1

    Drug: Recombinant human thrombopoietin

  • Placebo comparator
    B2

    Drug: Placebo

  • Experimental
    C1-1

    Drug: Recombinant human thrombopoietin

  • Placebo comparator
    C1-2

    Drug: Placebo

  • Experimental
    C2-1

    Drug: recombinant human thrombopoietin

  • Placebo comparator
    C2-2

    Drug: placebo

  • Experimental
    C3-1

    Drug: Recombinant human thrombopoietin

  • Placebo comparator
    C3-2

    Drug: placebo

Interventions

  • Recombinant human thrombopoietin will be administered single dose 300 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class A

    Also known as: rhTPO

  • Recombinant human thrombopoietin will be administered single dose 300 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class B.

    Also known as: rhTPO

  • DrugPlacebo

    Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class B.

  • Recombinant human thrombopoietin will be administered single dose 150 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C.

    Also known as: rhTPO

  • DrugPlacebo

    Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C

  • Recombinant human thrombopoietin will be administered single dose 300 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C.

    Also known as: rhTPO

  • Drugplacebo

    Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C

  • Recombinant human thrombopoietin will be administered single dose 450 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C.

    Also known as: rhTPO

  • Drugplacebo

    Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C

06

What researchers measure

Primary outcomes

  1. Safety and tolerability as assessed by the collection of adverse events

    To evaluate the adverse events (incidence, severity, outcome, causality with the investigational drug, etc.).

    Time frame: Up to 29 days

  2. AUC[0-24]of rhTPO

    To assess plasma rhTPO Pharmacokinetic (PK) Parameter: Area under the concentration-time curve from time zero extrapolated to 24 hours(AUC \[0-24\]).

    Time frame: For 9 days

  3. AUC [0-t] of rhTPO

    To assess plasma rhTPO PK Parameter: Area under the concentration-time curve from time zero to last time of quantifiable concentration(AUC \[0-t\]).

    Time frame: For 9 days

  4. AUC [0-∞]of rhTPO

    To assess plasma rhTPO PK Parameter: area under the concentration-time curve from time zero extrapolated to infinity(AUC \[0-∞\]).

    Time frame: For 9 days

  5. Cmax of rhTPO

    To assess plasma rhTPO PK Parameter:Observed maximum plasma concentration(Cmax).

    Time frame: For 9 days

  6. tmax of rhTPO

    To assess plasma rhTPO PK Parameter:Time to Cmax (tmax).

    Time frame: For 9 days

  7. t1/2 of rhTPO

    To assess plasma rhTPO PK Parameter:Elimination half-life (t1/2).

    Time frame: For 9 days

  8. MRT for rhTPO

    To assess plasma rhTPO PK Parameter:Mean residence time (MRT).

    Time frame: For 9 days

  9. Kel of rhTPO

    To assess plasma rhTPO PK Parameter:Elimination rate constant (Kel).

    Time frame: For 9 days

  10. Vd of rhTPO

    To assess plasma rhTPO PK Parameter:Apparent volume of distribution(Vd).

    Time frame: For 9 days

  11. CL/F of rhTPO

    To assess plasma rhTPO PK Parameter:apparent clearance (CL/F).

    Time frame: For 9 days

Secondary outcomes

  1. Immunogenicity of rhTPO

    To evaluate the incidence of anti-rhTPO antibodies and neutralizing antibodies

    Time frame: Up to 12 months

  2. Change of Platelet count (PLT)

    To evaluate the changing curve of platelet count (PLT) in each arm of subjects

    Time frame: Up to 29 days

07

Study locations

1 of 1 sites recruiting
  • 302 Military Hospital of China
    Beijing, Beijing 100039, China
    Recruiting
    • Jinhua Hu, MD · Contact
    • Haibin Su, MD · Contactsuhaibin302@163.com
    • Jinhua HU, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2018 (actual). Primary completion is estimated for Oct 2020, 27 months after the start.

Of 32 phase 1 interventional studies under Liver Cirrhosis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 29. This study's planned 27 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2018
First posted
Sep 17, 2018
StartActual
Jun 28, 2018
Primary completionEst.
Oct 8, 2020
CompletionEst.
Dec 31, 2020
Last update
Mar 23, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03673215
Responsible party
Sponsor
First posted
Sep 17, 2018
Start date
Jun 28, 2018
Primary completion
Oct 8, 2020 (estimated)
Completion
Dec 31, 2020 (estimated)
Last update
Mar 23, 2020

Study contacts

Quanrui WU, Master
Contact
wuquanrui@3sbio.com
86 10 84892211
Sunqiong Cao, MD
Contact
caosunqiong@3sbio.com
86 10 84892211

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Recombinant human thrombopoietin

Start the discussion